{"filing":{"accession_number":"0001790340-26-000088","cik":"0001790340","ticker":"IMRX","company_name":"Immuneering Corp","form":"8-K","filing_date":"2026-08-05","report_date":"2026-08-05","primary_document":"imrx-20260805.htm","primary_document_url":"https://www.sec.gov/Archives/edgar/data/1790340/000179034026000088/imrx-20260805.htm"},"events":[{"id":25250,"run_id":22913,"accession_number":"0001790340-26-000088","anchor_item_number":"2.02","event_type":"earnings_release","event_domain":"financial","is_material":true,"confidence":0.95,"summary":"This is a quarterly earnings release for Q2 2026 ended June 30, 2026, disclosing financial results including R\u0026D expenses ($14.0M), G\u0026A expenses ($5.0M), net loss ($17.3M or $0.27 per share), and cash position ($182.7M). The press release is furnished as Exhibit 99.1 and includes condensed consolidated financial statements. Material to investors as it reports the company's financial condition and operational performance for the period.","company_name":"Immuneering Corp","ticker":"IMRX","filing_date":"2026-08-05","form":"8-K","submitted_at":null,"items":[{"id":26027,"accession_number":"0001790340-26-000088","item_number":"2.02","item_title":"Results of Operations and Financial Condition.","event_type":"earnings_release","event_domain":"financial","is_material":true,"confidence":0.95,"reasoning":"This is a quarterly earnings release for Q2 2026 ended June 30, 2026, disclosing financial results including R\u0026D expenses ($14.0M), G\u0026A expenses ($5.0M), net loss ($17.3M or $0.27 per share), and cash position ($182.7M). The press release is furnished as Exhibit 99.1 and includes condensed consolidated financial statements. Material to investors as it reports the company's financial condition and operational performance for the period.","classifier_version":"claude-haiku-4-5-20251001+prompt-a85dd512","taxonomy_version":"v1.3","classified_at":"2026-08-08T02:22:52.879367+00:00","company_name":"","ticker":null,"filing_date":""}]}],"classifications":[{"id":26027,"accession_number":"0001790340-26-000088","item_number":"2.02","item_title":"Results of Operations and Financial Condition.","event_type":"earnings_release","event_domain":"financial","is_material":true,"confidence":0.95,"reasoning":"This is a quarterly earnings release for Q2 2026 ended June 30, 2026, disclosing financial results including R\u0026D expenses ($14.0M), G\u0026A expenses ($5.0M), net loss ($17.3M or $0.27 per share), and cash position ($182.7M). The press release is furnished as Exhibit 99.1 and includes condensed consolidated financial statements. Material to investors as it reports the company's financial condition and operational performance for the period.","classifier_version":"claude-haiku-4-5-20251001+prompt-a85dd512","taxonomy_version":"v1.3","classified_at":"2026-08-08T02:22:52.879367+00:00","company_name":"Immuneering Corp","ticker":"IMRX","filing_date":"2026-08-05"}]}